171 related articles for article (PubMed ID: 38664697)
1. Synergistic effect of human uterine cervical mesenchymal stem cell secretome and paclitaxel on triple negative breast cancer.
Eiro N; Fraile M; Escudero-Cernuda S; Sendon-Lago J; Gonzalez LO; Fernandez-Sánchez ML; Vizoso FJ
Stem Cell Res Ther; 2024 Apr; 15(1):121. PubMed ID: 38664697
[TBL] [Abstract][Full Text] [Related]
2. Riluzole synergizes with paclitaxel to inhibit cell growth and induce apoptosis in triple-negative breast cancer.
Speyer CL; Bukhsh MA; Jafry WS; Sexton RE; Bandyopadhyay S; Gorski DH
Breast Cancer Res Treat; 2017 Nov; 166(2):407-419. PubMed ID: 28780701
[TBL] [Abstract][Full Text] [Related]
3. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
[TBL] [Abstract][Full Text] [Related]
4. Adipose derived mesenchymal stem cell secretome formulation as a biotherapeutic to inhibit growth of drug resistant triple negative breast cancer.
Nadesh R; Menon KN; Biswas L; Mony U; Subramania Iyer K; Vijayaraghavan S; Nambiar A; Nair S
Sci Rep; 2021 Dec; 11(1):23435. PubMed ID: 34873206
[TBL] [Abstract][Full Text] [Related]
5. Synergistic Anti-Tumor Effect of Toosendanin and Paclitaxel on Triple-Negative Breast Cancer via Regulating ADORA2A-EMT Related Signaling.
Zhang J; Xu HX; Wu YL; Cho WCS; Xian YF; Lin ZX
Adv Biol (Weinh); 2023 Aug; 7(8):e2300062. PubMed ID: 37401656
[TBL] [Abstract][Full Text] [Related]
6. Anti-cell growth and anti-cancer stem cell activities of the non-canonical hedgehog inhibitor GANT61 in triple-negative breast cancer cells.
Koike Y; Ohta Y; Saitoh W; Yamashita T; Kanomata N; Moriya T; Kurebayashi J
Breast Cancer; 2017 Sep; 24(5):683-693. PubMed ID: 28144905
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-101 inhibits cell progression and increases paclitaxel sensitivity by suppressing MCL-1 expression in human triple-negative breast cancer.
Liu X; Tang H; Chen J; Song C; Yang L; Liu P; Wang N; Xie X; Lin X; Xie X
Oncotarget; 2015 Aug; 6(24):20070-83. PubMed ID: 26036638
[TBL] [Abstract][Full Text] [Related]
8. Low Dose of Paclitaxel Combined with XAV939 Attenuates Metastasis, Angiogenesis and Growth in Breast Cancer by Suppressing Wnt Signaling.
Shetti D; Zhang B; Fan C; Mo C; Lee BH; Wei K
Cells; 2019 Aug; 8(8):. PubMed ID: 31416135
[TBL] [Abstract][Full Text] [Related]
9. Sulforaphane enhances the anticancer activity of taxanes against triple negative breast cancer by killing cancer stem cells.
Burnett JP; Lim G; Li Y; Shah RB; Lim R; Paholak HJ; McDermott SP; Sun L; Tsume Y; Bai S; Wicha MS; Sun D; Zhang T
Cancer Lett; 2017 May; 394():52-64. PubMed ID: 28254410
[TBL] [Abstract][Full Text] [Related]
10. Potential therapeutic effect of the secretome from human uterine cervical stem cells against both cancer and stromal cells compared with adipose tissue stem cells.
Eiró N; Sendon-Lago J; Seoane S; Bermúdez MA; Lamelas ML; Garcia-Caballero T; Schneider J; Perez-Fernandez R; Vizoso FJ
Oncotarget; 2014 Nov; 5(21):10692-708. PubMed ID: 25296979
[TBL] [Abstract][Full Text] [Related]
11. A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer.
Desroys du Roure P; Lajoie L; Mallavialle A; Alcaraz LB; Mansouri H; Fenou L; Garambois V; Rubio L; David T; Coenon L; Boissière-Michot F; Chateau MC; Ngo G; Jarlier M; Villalba M; Martineau P; Laurent-Matha V; Roger P; Guiu S; Chardès T; Gros L; Liaudet-Coopman E
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38290768
[TBL] [Abstract][Full Text] [Related]
12. Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin.
Kai M; Kanaya N; Wu SV; Mendez C; Nguyen D; Luu T; Chen S
Breast Cancer Res Treat; 2015 Jun; 151(2):281-94. PubMed ID: 25904215
[TBL] [Abstract][Full Text] [Related]
13. An in vitro study on the reversal of epithelial to mesenchymal transition by brusatol and its synergistic properties in triple-negative breast cancer cells.
Chandrasekaran J; Balasubramaniam J; Sellamuthu A; Ravi A
J Pharm Pharmacol; 2021 Apr; 73(6):749-757. PubMed ID: 33769483
[TBL] [Abstract][Full Text] [Related]
14. The GEF-H1/PKD3 signaling pathway promotes the maintenance of triple-negative breast cancer stem cells.
Lieb WS; Lungu C; Tamas R; Berreth H; Rathert P; Storz P; Olayioye MA; Hausser A
Int J Cancer; 2020 Jun; 146(12):3423-3434. PubMed ID: 31745977
[TBL] [Abstract][Full Text] [Related]
15. PRKCQ inhibition enhances chemosensitivity of triple-negative breast cancer by regulating Bim.
Byerly JH; Port ER; Irie HY
Breast Cancer Res; 2020 Jun; 22(1):72. PubMed ID: 32600444
[TBL] [Abstract][Full Text] [Related]
16.
Sendon-Lago J; Seoane S; Saleh F; Garcia-Caballero L; Arias ME; Eiro N; Macia M; Vizoso FJ; Perez-Fernandez R; Schneider J
Cancer Genomics Proteomics; 2022; 19(5):570-575. PubMed ID: 35985689
[TBL] [Abstract][Full Text] [Related]
17. Targeting claudin-4 enhances chemosensitivity in breast cancer.
Luo Y; Kishi S; Sasaki T; Ohmori H; Fujiwara-Tani R; Mori S; Goto K; Nishiguchi Y; Mori T; Kawahara I; Kondoh M; Kuniyasu H
Cancer Sci; 2020 May; 111(5):1840-1850. PubMed ID: 32086991
[TBL] [Abstract][Full Text] [Related]
18. Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer.
Arango NP; Yuca E; Zhao M; Evans KW; Scott S; Kim C; Gonzalez-Angulo AM; Janku F; Ueno NT; Tripathy D; Akcakanat A; Naing A; Meric-Bernstam F
Breast Cancer Res; 2017 Aug; 19(1):93. PubMed ID: 28810913
[TBL] [Abstract][Full Text] [Related]
19. Conditioned Medium of Mesenchymal Stromal Cells Loaded with Paclitaxel Is Effective in Preclinical Models of Triple-Negative Breast Cancer (TNBC).
Cordani N; Lisini D; Coccè V; Paglia G; Meanti R; Cerrito MG; Tettamanti P; Bonaffini L; Paino F; Alessandri G; Marcianti A; Giannì A; Villa C; Mauri M; Mologni L; Torsello A; Pessina A; Cazzaniga ME
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982938
[TBL] [Abstract][Full Text] [Related]
20. Macrophage-Derived Extracellular Vesicles as Drug Delivery Systems for Triple Negative Breast Cancer (TNBC) Therapy.
Haney MJ; Zhao Y; Jin YS; Li SM; Bago JR; Klyachko NL; Kabanov AV; Batrakova EV
J Neuroimmune Pharmacol; 2020 Sep; 15(3):487-500. PubMed ID: 31722094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
